Cell Signaling Technology

Product Pathways - Lymphocyte Signaling

p67phox Antibody #3923

Applications Reactivity Sensitivity MW (kDa) Source
W H M R Endogenous 67 Rabbit

Applications Key:  W=Western Blotting
Reactivity Key:  H=Human  M=Mouse  R=Rat
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Protocols

Specificity / Sensitivity

p67phox Antibody detects endogenous levels of total p67phox protein.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala25 of human p67phox. Antibodies are purified by protein A and peptide affinity chromatography.

Western Blotting

Western Blotting

Western blot analysis of extracts from RAW 264.7 and C6 cells using p67phox Antibody.

Background

The phagocytic NADPH oxidase is a multiprotein enzyme that catalyzes the reduction of oxygen to superoxide in response to pathogenic invasion. The NADPH oxidase consists of 6 subunits, including the membrane-bound p91 phox and p22 phox heterodimers (also known as cytochrome b558), the cytosolic complex of p40phox, p47phox and p67phox, and the small GTPase Rac2. Activation of NADPH oxidase is initiated by cytosolic complex phosphorylation, which induces a conformational change that leads to the translocation of the cytosolic complex to the membrane and formation of an active enzyme with cytochrome b558 (1). Defects in p47phox, often resulting from recombination between p47phox and a nearby homologous pseudogene, cause chronic granulomatous disease (2-4). Elevated oxidative stress due to increased myocardial NADPH oxidase activity may be a contributing factor in heart failure (5,6).

p67phox appears to coordinate assembly of NAPDH oxidase as it associates with multiple subunits as well as the α subunit of heterotrimeric G proteins (7). Mutations in the corresponding p67phox gene are also associated with a form of autosomal recessive chronic granulomatous disease (8).

  1. Babior, B.M. (1999) Blood 93, 1464-76.
  2. Noack, D. et al. (2001) Blood 97, 305-11.
  3. Görlach, A. et al. (1997) J Clin Invest 100, 1907-18.
  4. Chanock, S.J. et al. (2000) Blood Cells Mol Dis 26, 37-46.
  5. Heymes, C. et al. (2003) J Am Coll Cardiol 41, 2164-71.
  6. Doerries, C. et al. (2007) Circ Res 100, 894-903.
  7. Marty, C. et al. (2006) Mol Cell Biol 26, 5190-200.
  8. Leto, T.L. et al. (1990) Science 248, 727-30.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.

Products